Axsome Therapeutics Inc. (NASDAQ:AXSM) is one of the best mid-cap growth stocks to buy right now. On January 16, Piper Sandler raised its price target on Axsome Therapeutics to $223 from$148 with an Overweight rating. Piper Sandler is confident in Auvelity’s commercial potential, particularly given the highly likely FDA label expansion into Alzheimer’s agitation expected by April 30 this year. The optimism is further supported by the drug’s sustained momentum in the depression market and a long-term paten ...